Sonic Hedgehog Pathway Blockade After Surgical Debulk of Large Exophytic Basal Cell Carcinomas
In 2012, the FDA approved vismodegib (Erivedge Genentech, Inc.) for locally advanced basal cell carcinoma (BCC) in addition to other indications. Hedgehog pathway inhibitors have been used as sole therapy as well as adjuvant and neoadjuvant treatment, before definitive surgical management. In the following cases, we describe the utility of surgically debulking large exophytic BCCs before hedgehog pathway inhibitor use to hasten response to the hedgehog inhibitor, decrease duration of therapy, minimize side effects, and potentially decrease recurrence.
Files
Metadata
| Work Title | Sonic Hedgehog Pathway Blockade After Surgical Debulk of Large Exophytic Basal Cell Carcinomas |
|---|---|
| Access | |
| Creators |
|
| License | In Copyright (Rights Reserved) |
| Work Type | Article |
| Publisher |
|
| Publication Date | August 1, 2021 |
| Publisher Identifier (DOI) |
|
| Deposited | March 06, 2023 |
Versions
Analytics
Collections
This resource is currently not in any collection.